← Browse by Condition
Medical Condition

primary open angle glaucoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for primary open angle glaucoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — primary open angle glaucoma Clinical Trials

How many clinical trials are currently recruiting for primary open angle glaucoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for primary open angle glaucoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for primary open angle glaucoma?
primary open angle glaucoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a primary open angle glaucoma clinical trial?
Eligibility criteria for primary open angle glaucoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University of Alabama at Birmingham 1 trial
Cairo University 1 trial
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. 1 trial
The Eye Institute of West Florida 1 trial

Recruiting Clinical Trials

NCT04396002
Recruiting
Glaucoma, Visual Field Loss, and Their Association With Life Space in Older Adults
Enrollment
100 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT07599241
Recruiting
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
Enrollment
40 pts
Location
Egypt
Sponsor
Cairo University
View Trial →
NCT07777861 Phase 2
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
Enrollment
90 pts
Location
China
Sponsor
Qingdao WanMing BioCell Pharma...
View Trial →
NCT07390890
Recruiting
DSLT for Reducing Medication in Glaucoma
Enrollment
60 pts
Location
United States
Sponsor
The Eye Institute of West Flor...
View Trial →

Related Conditions

subclinical hypothyro dism (1) non alcoholic fatty liver disease (1) optic nerve injury (1) ocular hypertension (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology